教員データベース - 小阪　嘉之

コサカ　ヨシユキ KOSAKA YOSHIYUKI
小阪　嘉之

所属

神戸学院大学総合リハビリテーション学部作業療法学科

職種教授

学会発表
2024/10/25	兵庫県における小児血液腫瘍疾患の施設連携－血友病中心に新規治療薬含めて―
2024/09/06	当院における血友病B診療―特にPUPs治療の考え方と地域連携について―
2024/07/20	小児血液腫瘍分野を志す医師の減少に対する傾向と対策について考える
2024/07/06	小児血液・腫瘍疾患up-to-date \n ―人気のないこの領域に少しでも興味をもっていただきたくて―
2024/05/24	当院における血友病治療の現状と課題－PUPs
2024/05/15	小児専門施設における血液・腫瘍疾患の移行期医療の現状と課題－小児がんと血友病中心に―
2024/04/05	血友病保因者ケアの現状と課題
2023/12/04	小児専門施設における小児血友病A治療の現状と課題
2023/11/16	小児科におけるヘムライブラの適応と課題を考える
2023/09/22	当院における小児血友病救急診療の現状
2023/09/13	小児専門病院・血友病地域中核病院における血友病診療の現状と課題ー頭蓋内出血対策中心にー
2023/09/09	当院におけるPUPs治療の現状と課題
2023/02/21	当院における血友病未治療例(PUPs)の治療について
2022/12/23	小児専門施設における血友病診療の現状－医療連携と移行期医療含め―
2022/12/13	当院における乳幼児血友病、特に未治療例(PUPs)の治療について
2022/12/08	小児版チェックシートの活用法
2022/12/02	小児専門病院における血友病地域中核病院の現状と課題
2022/06/30	乳幼児血友病診療について考える―頭蓋内出血とインヒビターをいかに回避するか―
2022/04/12	当院の乳幼児血友病診療の考え方－PUPsと頭蓋内出血中心に―
2022/04/02	兵庫県における血液腫瘍疾患の病院連携について―血友病中心に―
2022/01/08	当院における造血幹細胞移植～SOS対策の変遷含めて～
2021/12/09	診療連携地域中核病院の現状と課題について
2021/10/30	血友病患者における頭蓋内出血－当院の経験と課題－
2021/10/28	移行期医療の現状と課題－血友病を中心に送り出す側の観点から―
2021/08/19	未治療の血友病患者さん(PUPs)に対する治療を考える―半減期延長製剤の使用経験を含めて―
2021/07/07	小児専門施設の血友病診療連会―地域中核病院としての役割と課題―
2021/03/11	当院における血友病診療連携中核病院としての血友病診療
2020/01/16	血友病診療の現状
2019/12/01	小児がんってどんな病気？大人のがんとどこが違うの？
2019/10/16	当科における血友病
2019/09/20	血友病治療の革新
2019/08/02	当院における血友病診療
2019/02/14	血友病診療の現状と課題
2019/02/01	小児がんに伴う晩期合併症と病院連携
2018/10/27	PUPsに対する半減期延長製剤の使用経験
2018/10/16	小児がんの晩期合併症と長期フォローアップ
2018/10/05	小児がん診療の現状と課題
2018/09/22	血友病に対する定期補充導入の最適時期を考える
2018/08/30	定期補充療法の適切な導入時期を考える
2018/08/02	当院における血友病診療
2018/06/22	当科における定期補充療法導入
2018/03/17	小児専門施設における血友病診療－定期補充療法への提案
2018/01/13	小児がんの特徴と治療について
2017/12/12	小児がんを知るー笑顔のためにできること
2017/06/30	出血傾向のある子供に対する学校との連携
2017/05/14	小児がんについて―小児がんを正しく知ってください
2016/12	Continuous cytarabine plus dexamethasone in consolidation phase to patients with childhood ALL: result from Japan Association of Childhood Leukemia Study -- JACLS ALL02 protocol. (Annual Meeting of Maerican Society of Hematology)
2016/12	Landscape of Driver Mutations and Their Clinical Impacts in Pediatric Acute Lymphoblastic Leukemia (Annual Meeting of Maerican Society of Hematology)
2016/12	Risk-adjusted therapy of acute lymphoblastic leukemia can improve survival: Results of Japan Association Childhood Leukemia Study Group (JACLS) Protocol ALL-02 (Annual Meeting of Maerican Society of Hematology)
2016/12	Shift to Anti-Fibrinolysis on the Administration of L-Asparaginase (L-Asp) during Induction Therapy for Pediatric Acute Lymphoblastic Leukemia (ALL) (Annual Meeting of Maerican Society of Hematology)
2016/12	The outcome of low-risk childhood B-cell precursor ALL treated with the Japan Association of childhood Leukemia Study (JACLS) ALL-02 trial. (Annual Meeting of Maerican Society of Hematology)
2016/09/05	小児造血器腫瘍の診断と治療ー“こどもの白血病”は“おとなの白血病”とどこが違う？
2016/07/23	当院における血友病診療～定期補充療法導入についての提言〜
2016/05/14	血栓性血小板減少性紫斑病(TTP)/溶血性尿毒症症候群(HUS)の病態と治療
2016/04	Effects of conditioning intensity on growth after hematopoietic stem cell transplantation in children. (Annual Meeting of the European Society for Blood and Marrow Transplantation)
2016/03/26	小児がんをとりまく最近の動向\n－小児がん拠点病院と新病院における小児がん診療について－
2015/11/27	小児血液疾患における遺伝子組み換えトロンボモジュリン製剤(rTM)の役割
2015/08/22	当院における脳腫瘍の化学療法、自家末梢血幹細胞移植併用大量化学療法について
2015/07/29	小児血液疾患におけるｒTMの使用経験ー移植症例含めて
2015/04	Neuroblastoma minimal residual disease markers are differentially expressed in peripheral blood and bone marrow samples (Asian Society of Pediatric Research 2015)
2015/04	Two high-risk neuroblastoma cases with early detection of tumor relapse/re-growth by consecutive minimal residual disease monitoring (Asian Society of Pediatric Research 2015)
2014/12	Absolute lymphocyte counts at the end of induction is a prognostic indicator in childhood acute lymphoblastic leukemia. (Annual Meeting of American Society of Hematology)
2014/12	Clinical Significance of LNK (SH2B3) Expression in Pediatric B Cell Precursor Acute Lymphoblastic Leukemia. (Annual Meeting of Maerican Society of Hematology)
2014/12	Differentiating Burkitt Lymphoma from Burkitt-like Lymphoma in Pediatrics: Report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 Study (Annual Meeting of Maerican Society of Hematology)
2014/12	High Event-Free Survival Rate with Minimum-Dose-Anthracycline Treatment in Childhood Acute Promyelocytic Leukemia: A Nationwide Prospective Study By the Japanese Pediatric Leukemia / Lymphoma Study Group (JPLSG) (Annual Meeting of Maerican Society of Hematology)
2014/11/22	当院における自家末梢血幹細胞移植
2014/09	Aggressiveness of End of Life care for Neuroblastoma Patients (International Society of Pediatric Oncology)
2014/06	High dose topotecan, melphalan, and cyclophosphamide (TMC) with autologous peripheral blood stem cell transplant for advanced medulloblastoma, supratentorial primitive neuroectodermal tumors, and pineoblastoma (International Symposium Pediatric Oncology)
2014/03/16	関西における小児がん拠点病院の役割
2014/01/26	頭蓋内胚細胞腫瘍に対する強力化学療法
2013/12	Poor Prognosis With Different Induction Rate Was Observed In Children With Acute Myeloid Leukemia and FLT3-ITD According To The ITD/WT Allelic Ratio: A Result From The Japanese Pediatric Leukemia/Lymphoma Study Group (Annual Meeting of American Society of Hematology)
2013/12	Prognostic Significance Of CRLF2 Over-Expression In Pediatric Acute Lymphoblastic Leukemia (Annual Meeting of American Society of Hematology)
2013/12	Risk Factors for Clonal Evolution Of Acquired Bone Marrow Failure After Immunosuppressive Therapy In Children. (Annual Meeting of American Society of Hematology)
2013/09/28	小児がんにおけるチーム医療ー特に麻酔科のかかわりについて
2013/09	THE Feasibility of High-dose Topotecan, Melphalan and Cyclophosphamide in Children with Advanced solid Tumors: A Single-Institution Experience. (Congrenn of International society of Pediatric Oncology)
2012/12	Appropriate Dose Modification in Induction Therapy Is Essential for the Treatment of Infants with Acute Myeloid Leukemia; A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). (Annual Meeting of American Society of Hematology)
2012/12	Attempts to Optimize Post-Induction Treatment in Childhood Acute Myeloid Leukemia without Core Binding Factors: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) (Annual Meeting of American Society of Hematology)
2012/12	Excess Reduction of Anthracyclines Results in Inferior Event-Free Survival in Core Binding Factor Acute Myeloid Leukemia in Children; A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) (Annual Meeting of American Society of Hematology)
2012/03/10	近畿地区における小児がん全例登録の取り組み
2011/12	Antithymocyte Globulin (ATG), Cyclosporine (CyA), and Danazol Versus ATG and CyA As Treatment for Children with Aplastic Anemia: Result of Matched-Pair Analysis (Annual Meeting of American Society of Hematology)
2011/12	IKZF1 Deletion Is Strongly Associated with Risk of Relapse in Intermediate Risk Group in JACLS ALL02 Cohort (Annual Meeting of American Society of Hematology)
2011/12	JAK2 mutations and CRLF2 rearrangements in Down Syndrome-Associated Acute Lymphoblastic Leukemia in Japan (Annual Meeting of American Society of Hematology)
2011/12	Outcomes in Children with Severe Aplastic Anemia Receiving Bone Marrow Transplantation from an HLA-Matched Family Donor or Intensive Immunosuppressive Therapy As First-Line Treatment (Annual Meeting of American Society of Hematology)
2011/02/17	小児白血病の診断と治療
2009/12	Mutations in Ribosomal Protein Genes of Diamond-Blackfan Anemia Patients in Japan (Annual meeting of American Society of Hematology)
2008/12	Predicting Response to Immunosuppressive Therapy in Childhood Aplastic Anemia. (Annual Meeting of American Society of Hematology)
2008/12	Relapse of Children with Aplastic Anemia after Immunosuppressive Therapy (Annual Meeting of American Society of Hematology)
2008/05	Expression of HER2/neu is Uncommon in Childhood Neuroblastomas but not in Human Neuroblastoma Cell Lines (Advances Neuroblastoma Research 2008)
2008/04	Clonal expansion of an MLL-AF3p21 fusion gene in the absence of leukaemia (Congress of the European Hematology Association)
2007/12	Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia (Annual Meeting of American Society of Hematology ()